Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00422617
Status:
COMPLETED
Last Update Posted:
2007-01-17
First Post:
2007-01-16
Brief Title:
Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients
Sponsor:
Uni-Pharma
Organization:
Uni-Pharma
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2004-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open-label multicentre study to evaluate the efficacy and safety of one course of weekly intramuscular administration of Amevive in Taiwan patients with chronic plaque psoriasis
Detailed Description:
The purpose of the present study is to establish the efficacy and safety of one course of once weekly 15 mg intramuscular IM administration of AMEVIVE in an alternate study population and to address the issue of peak time to response by measuring the proportion of patients achieving a 75 reduction in PASI at any time after completion of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None